scholarly journals Combined treatment for female genital cancer

2021 ◽  
Vol 43 (2) ◽  
pp. 56-58
Author(s):  
N. E. Sidorov ◽  
N. L. Kapelyushnik
Keyword(s):  
Lymph Nodes ◽  
Combined Therapy ◽  
Uterine Cancer ◽  
Combined Treatment ◽  
Genital Cancer ◽  
Female Genital

Obstetric and gynecological clinic of Kazan GIDUV for 40 years of its activity in the treatment of uterine cancer, as a rule, used combined therapy. In the first 2 decades, during the operation, attention was focused on the removal of parametric tissue. Experience has shown the insufficiency of such an intervention for long-term recovery. Relapses were frequent in the stump of the vagina, pelvic tissue, and lymph nodes.

scholarly journals Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients

2009 ◽  
Vol 160 (4) ◽  
pp. 529-533 ◽  
Author(s):  
SJCMM Neggers ◽  
WW de Herder ◽  
JAMJL Janssen ◽  
RA Feelders ◽  
AJ van der Lely
Keyword(s):  
Combined Therapy ◽  
Combined Treatment ◽  
Somatostatin Analogs ◽  
Pituitary Surgery ◽  
Median Dosage ◽  
Previously Treated ◽  
Long Acting

BackgroundWe previously reported on the efficacy, safety, and quality of life (QoL) of long-acting somatostatin analogs (SSA) and (twice) weekly pegvisomant (PEG-V) in acromegaly and improvement after the addition of PEG-V to long-acting SSA.ObjectiveTo assess the long-term safety in a larger group of acromegalic patients over a larger period of time: 29.2 (1.2–57.4) months (mean (range)).DesignPegvisomant was added to SSA monotherapy in 86 subjects (37 females), to normalize serum IGF1 concentrations (n=63) or to increase the QoL. The median dosage was 60.0 (20–200) mg weekly.ResultsAfter a mean treatment period of 29.2 months, 23 patients showed dose-independent PEG-V related transient liver enzyme elevations (TLEE). TLEE occurred only once during the continuation of combination therapy, but discontinuation and re-challenge induced a second episode of TLEE. Ten of these patients with TLEE also suffered from diabetes mellitus (DM). In our present series, DM had a 2.28 odds ratio (CI 1.16–9.22; p=0.03) higher risk for developing TLEE. During the combined therapy, a clinical significant decrease in tumor size by more than 20% was observed in 14 patients. Two of these patients were previously treated by pituitary surgery, 1 with additional radiotherapy and all other patients received primary medical treatment.ConclusionLong-term combined treatment with SSA and twice weekly PEG-V up to more than 4 years seems to be safe. Patients with both acromegaly and DM have a 2.28 higher risk of developing TLEE. Clinical significant tumor shrinkage was observed in 14 patients during combined treatment.

Four Years' Follow-up Results of Three Different Percutaneous Treatments for Male Varicocele

1999 ◽  
Vol 14 (2) ◽  
pp. 48-53
Author(s):  
M. Pocek ◽  
M. R. Guazzaroni ◽  
G. Sodani ◽  
M. N. Guazzaroni ◽  
R. Cancellieri ◽  
...  
Keyword(s):  
Combined Therapy ◽  
Combined Treatment ◽  
Duplex Ultrasound ◽  
Fourth Degree ◽  
The Third ◽  
University Of Rome ◽  
Radiological Procedures ◽  
Gianturco Coils

Objective: To evaluate the efficacy of three different interventional radiological procedures for the treatment of venous reflux in symptomatic male varicocele. Design: Prospective study with a 48-month colour duplex ultrasound (CD) follow-up. Setting: Department of Radiology, Tor Vergata University of Rome. Patients: From January 1991 to December 1993, 45 symptomatic patients with third- to fourth-degree varicocele, according to Sarteschi's CD classification, were randomly divided into three equal groups (15 patients each). Interventions: The first group received sclerotherapy (Athoxysclerol), the second underwent embolisation (Gianturco coils), while the third group received combined sclero–embolisation therapy (Athoxysclerol and Gianturco coils). Main outcomes measures: The frequency of recurrence for each procedure. Results: Two recurrences (13%) after 1 and 2 years occurred in patients who underwent sclerotherapy. In the embolisation group, two patients showed residual varices (13%). Neither recurrence nor residue was seen in the third group, who received combined therapy. Conclusions: Sclerotherapy provides good immediate results but drug dilution may cause a relapse shortly after treatment. Embolisation has a lower immediate success but better long-term success. Combined treatment provides the highest long-term success rate.

scholarly journals The use of in vivo dosimetry within the combined treatment of uterine body cancer

2020 ◽  
Vol 55 (1) ◽  
pp. 35-38
Author(s):  
O. M. Sukhina ◽  
V. S. Sukhin ◽  
Y. B. Radzishevska ◽  
A. S. Sіmbіrova
Keyword(s):  
Cancer Patients ◽  
Linear Accelerator ◽  
Uterine Cancer ◽  
Combined Treatment ◽  
Relative Difference ◽  
In Vivo Dosimetry ◽  
Genital Cancer ◽  
Post Surgery ◽  
The Impact

Relevance: Radiotherapy is the standard post-surgery treatment in patients with uterine cancer. However, radiotherapy affects 90.0–100.0% of the volume of risk organs. Information on the actual dose delivered to critical structures is needed to ensure the quality of radiotherapy. The purpose of this study was to determine the impact of the type of ionizing radiation on the dose load on the rectal mucosa using in vivo dosimetry. Results: At the first and tenth sessions of treatment using a cobalt apparatus, the in vivo dosimetry showed that the minimum value of the dose received during the tenth cycle was higher by 0.1 Gy. That is, the deviations from the planned dose were less at the same maximum values. Both the average value and the median during the tenth cycle were also moderately higher. The relative difference between the dose planned and received during the tenth cycle was higher than during the first cycle by an average of 1.12575%, with a median of 0.82214. When conducting radiotherapy using a linear accelerator, the average and median values were higher in the second measurement despite almost identical minimum and maximum values. The relative difference between the planned and received doses during the tenth cycle was higher than during the first cycle by an average of 0.55619%, with a median of 0.42948. Conclusion: The conducted study showed an intro- and interindividual variability of in vivo dosimetry results during radiotherapy of genital cancer patients. In vivo dosimetric control showed that the relative difference between the doses calculated and received by the rectal mucosa upon reaching of 20.0 Gy dose in comparison to the first irradiation cycle were twice higher on the ROCUS-AM cobalt apparatus vs. the Clinac 600 C linear accelerator. The data obtained during the investigation indicates the need to develop innovative approaches to topometric preparation of genital cancer patients and to continue their dosimetric monitoring to establish the causes of discrepancies in the results.

scholarly journals Effect of long-term treatment with fenspiride (Erespal) on clinical and functional status of patients with chronic obstructive lung disease

2005 ◽  
pp. 92-94
Author(s):  
A. A. Visel ◽  
E. Yu. Pronina ◽  
I. Yu. Visel ◽  
M. A. Yunusova
Keyword(s):  
Combined Therapy ◽  
Randomized Study ◽  
Combined Treatment ◽  
Chronic Obstructive Lung Disease ◽  
Term Treatment ◽  
Chronic Obstructive ◽  
Copd Patients ◽  
Long Term Treatment ◽  
Clinical And Functional Status

This open comparative randomized study has shown that fenspiride is an effective and well-tolerated drug while being administered in combined therapy of COPD for 3 to 12 months. The anti-inflammatory action of fenspiride 80 mg t. i. d. significantly reduced cough in COPD patients and enhanced the effect of bronchodilators. Fenspiride (Erespal) can be included in standards of combined treatment of patients with mild, moderate and severe COPD.

COMBINATION OF POTASSIUM PERCHLORATE AND PROPYLTHIOURACIL IN THE TREATMENT OF THYROTOXICOSIS

1968 ◽  
Vol 57 (4) ◽  
pp. 565-577 ◽  
Author(s):  
K. E. Røkke ◽  
J. H. Vogt
Keyword(s):  
Drug Therapy ◽  
Side Effects ◽  
Metabolic Rate ◽  
Total Cholesterol ◽  
Basal Metabolic Rate ◽  
Combined Therapy ◽  
Combined Treatment ◽  
Control Measures ◽  
Potassium Perchlorate ◽  
Plasma Total Cholesterol

ABSTRACT A report is given on 95 thyrotoxic patients treated with a combination of 400 mg propylthiouracil and 400 mg of potassium perchlorate. Perchlorate was stopped when a marked remission of symptoms was obtained, on an average after less than 7 weeks. Euthyroidism was found on an average after 7.2 weeks. The basal metabolic rate, PBI, plasma total cholesterol and weight showed a fairly rapid normalization. Thirteen of the 95 patients were given radio-iodine therapy shortly before drug therapy was started. The remaining 82 cases were grouped together with the 23 cases previously reported. Of the total of 105 cases, 96 became euthyroid on combined therapy. For the frequency of side-effects, the thirteen cases mentioned above were included, giving a total of 118 cases. Eight cases showed an increase in goitre size and 15 cases had other side-effects, of which three were granulocytopenia due to propylthiouracil. The possibility of a higher frequency of mainly minor side-effects on combined therapy has to be balanced against the seemingly rapid and reliable therapeutic effect. Combined treatment, perhaps with even smaller doses than reported here, can be recommended in selected cases of thyrotoxicosis where a shortening of the thyrotoxic state seems of importance, or possibly where difficulties due to iodine exposure may be anticipated, provided adequate control measures are taken.

Analysis long-term results of combined treatment pellucid marginal degeneration

2020 ◽  
pp. 63-64
Author(s):  
I.V. Vasilieva ◽  
◽  
V.V. Egorov ◽  
S.V. Kostenev ◽  
A.V. Vasiliev ◽  
...  
Keyword(s):  
Combined Treatment ◽  
Long Term Results
Sign in / Sign up

Export Citation Format

Share Document